Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene.

Bonnevie-Nielsen V, Field LL, Lu S, Zheng DJ, Li M, Martensen PM, Nielsen TB, Beck-Nielsen H, Lau YL, Pociot F.

Am J Hum Genet. 2005 Apr;76(4):623-33. Epub 2005 Feb 24.

2.

OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes.

Field LL, Bonnevie-Nielsen V, Pociot F, Lu S, Nielsen TB, Beck-Nielsen H.

Diabetes. 2005 May;54(5):1588-91.

3.

Mitochondrial localization of the OAS1 p46 isoform associated with a common single nucleotide polymorphism.

Kjær KH, Pahus J, Hansen MF, Poulsen JB, Christensen EI, Justesen J, Martensen PM.

BMC Cell Biol. 2014 Sep 9;15:33. doi: 10.1186/1471-2121-15-33.

4.

Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan.

Imran M, Manzoor S, Khattak NM, Tariq M, Khalid M, Javed F, Bhatti S.

Viral Immunol. 2014 Apr;27(3):105-11. doi: 10.1089/vim.2013.0107. Epub 2014 Mar 27.

PMID:
24673406
5.

Induction and activation of antiviral enzyme 2',5'-oligoadenylate synthetase by in vitro transcribed insulin mRNA and other cellular RNAs.

Dan M, Zheng D, Field LL, Bonnevie-Nielsen V.

Mol Biol Rep. 2012 Jul;39(7):7813-22. doi: 10.1007/s11033-012-1624-x. Epub 2012 May 1.

PMID:
22547268
6.

Differential effects of a common splice site polymorphism on the generation of OAS1 variants in human bronchial epithelial cells.

Noguchi S, Hamano E, Matsushita I, Hijikata M, Ito H, Nagase T, Keicho N.

Hum Immunol. 2013 Mar;74(3):395-401. doi: 10.1016/j.humimm.2012.11.011. Epub 2012 Dec 5.

PMID:
23220500
7.

2'-5' oligoadenylate synthetase 1 polymorphism is associated with prostate cancer.

Mandal S, Abebe F, Chaudhary J.

Cancer. 2011 Dec 15;117(24):5509-18. doi: 10.1002/cncr.26219. Epub 2011 Jun 2.

8.

Long-term balancing selection at the antiviral gene OAS1 in Central African chimpanzees.

Ferguson W, Dvora S, Fikes RW, Stone AC, Boissinot S.

Mol Biol Evol. 2012 Apr;29(4):1093-103. doi: 10.1093/molbev/msr247. Epub 2011 Nov 21.

9.

OAS1: a multiple sclerosis susceptibility gene that influences disease severity.

O'Brien M, Lonergan R, Costelloe L, O'Rourke K, Fletcher JM, Kinsella K, Sweeney C, Antonelli G, Mills KH, O'Farrelly C, Hutchinson M, Tubridy N.

Neurology. 2010 Aug 3;75(5):411-8. doi: 10.1212/WNL.0b013e3181ebdd2b.

PMID:
20679634
10.

Impact of OAS1 Exon 7 rs10774671 Genetic Variation on Liver Fibrosis Progression in Egyptian HCV Genotype 4 Patients.

Bader El Din NG, Anany MA, Dawood RM, Ibrahim MK, El-Shenawy R, El Abd YS, El Awady MK.

Viral Immunol. 2015 Nov;28(9):509-16. doi: 10.1089/vim.2015.0041. Epub 2015 Oct 27.

PMID:
26505957
11.

Distinct antiviral roles for human 2',5'-oligoadenylate synthetase family members against dengue virus infection.

Lin RJ, Yu HP, Chang BL, Tang WC, Liao CL, Lin YL.

J Immunol. 2009 Dec 15;183(12):8035-43. doi: 10.4049/jimmunol.0902728.

12.

Characterization of the termini of the West Nile virus genome and their interactions with the small isoform of the 2' 5'-oligoadenylate synthetase family.

Deo S, Patel TR, Chojnowski G, Koul A, Dzananovic E, McEleney K, Bujnicki JM, McKenna SA.

J Struct Biol. 2015 May;190(2):236-49. doi: 10.1016/j.jsb.2015.04.005. Epub 2015 Apr 11.

PMID:
25871524
13.

The role of mouse 2',5'-oligoadenylate synthetase 1 paralogs.

Elkhateeb E, Tag-El-Din-Hassan HT, Sasaki N, Torigoe D, Morimatsu M, Agui T.

Infect Genet Evol. 2016 Nov;45:393-401. doi: 10.1016/j.meegid.2016.09.018. Epub 2016 Sep 21.

PMID:
27663720
14.

2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.

Haralambieva IH, Dhiman N, Ovsyannikova IG, Vierkant RA, Pankratz VS, Jacobson RM, Poland GA.

Hum Immunol. 2010 Apr;71(4):383-91. doi: 10.1016/j.humimm.2010.01.004. Epub 2010 Jan 31.

15.
16.

A human cellular noncoding RNA activates the antiviral protein 2'-5'-oligoadenylate synthetase 1.

Calderon BM, Conn GL.

J Biol Chem. 2018 Oct 12;293(41):16115-16124. doi: 10.1074/jbc.RA118.004747. Epub 2018 Aug 20.

17.

Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man.

Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM.

PLoS Pathog. 2009 Feb;5(2):e1000321. doi: 10.1371/journal.ppat.1000321. Epub 2009 Feb 27.

18.

Variability in the 2'-5'-oligoadenylate synthetase gene cluster is associated with human predisposition to tick-borne encephalitis virus-induced disease.

Barkhash AV, Perelygin AA, Babenko VN, Myasnikova NG, Pilipenko PI, Romaschenko AG, Voevoda MI, Brinton MA.

J Infect Dis. 2010 Dec 15;202(12):1813-8. doi: 10.1086/657418. Epub 2010 Nov 4.

PMID:
21050126
19.

Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection.

Yakub I, Lillibridge KM, Moran A, Gonzalez OY, Belmont J, Gibbs RA, Tweardy DJ.

J Infect Dis. 2005 Nov 15;192(10):1741-8. Epub 2005 Oct 12.

PMID:
16235172
20.

OAS1 gene haplotype confers susceptibility to multiple sclerosis.

Fedetz M, Matesanz F, Caro-Maldonado A, Fernandez O, Tamayo JA, Guerrero M, Delgado C, López-Guerrero JA, Alcina A.

Tissue Antigens. 2006 Nov;68(5):446-9.

PMID:
17092260

Supplemental Content

Support Center